Evaluation of the Neonatal Autonomic Stress During Intubations Under Propofol in a Population of Premature Infants Under 33 w'GA

NCT ID: NCT03721640

Last Updated: 2024-03-04

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 21 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-02-25
• Study Completion Date: 2022-08-23

Brief Summary

Hyaline membrane disease is one of the leading causes of morbidity and mortality in premature newborns in industrialized countries. For 30 years, the management of the hyaline membranes disease has been transformed by intratracheal administration of exogenous surfactant (Curosurf®) at birth or in the following hours. In order to limit the harmful effects in terms of barotrauma of mechanical ventilation, several methods have been developed over the last decades, aiming at limiting the mechanical ventilation to the profile of non-invasive ventilation: Thus the administration of surfactant has become faster (although invasive) and if possible followed by immediate extubation following the INSURE (INtubation / SURfactant / Extubation) or LISA (Less-Invasive Surfactant Administration) procedure.

Given the fragility of the children concerned and their low weight, this invasive gesture has long been carried out without premedication. However, taking into account the pain induced and potential hemodynamic consequences of the gesture, neonatal societies now recommend the use of anesthetic before intubation, with a short duration sedative.

Propofol is a general anesthetic that combines these conditions and is widely used in pediatric anesthesia.

In that way, since 2016, the invetigators have modified the sedation protocol for intubation in our department and have recommended Propofol as first-line treatment for term and preterm newborn. A lot of study showed its hemodynamic safety in preterms. However, the investigators lack data on the autonomic stress really observed during intubation in this population. The investigators therefore propose to evaluate these physiological data in a non-randomized prospective observational study in premature infants under 33 weeks of gestational amenorrhea (GA), during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique, with standardized doses of propofol : 1mg/kg for preterm infants with a birthweight less than 1.5kg and 1.5mg/kg for higher birthweight.

Conditions

Hyaline Membrane Disease; Preterm Infant

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Preterm neonates (< 33 weeks GA)

Preterm neonates requiring in the first week of life, an elective tracheal intubation for surfactant administration by INSURE or LISA methods.

electrocardiogram

Intervention Type: OTHER

Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.

Interventions

electrocardiogram

Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• breathing rate > 60 cycles/min
• Silverman scale > 3 and < 6
• FiO2 > 30% and < 60%
• collected consent from parents

Exclusion Criteria

• Preterm neonates with Intraventricular hemorrhage grade III & IV
• Preterm neonates with hemodynamic instability
• Preterm neonates with congenital heart disease
• Preterm neonates with severe congenital malformation
• Preterm neonates already sedated and/or under invasive mechanical ventilation
• FiO2 > 60%
• Silverman scale > 6
• Use of amines for maintaining blood pressure
• Use of sedatives or analgesics during the last 24 hours (except paracetamol and ibuprofen)

• Maximum Eligible Age: 33 Weeks
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire de Saint Etienne

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hugues PATURAL

Role: PRINCIPAL_INVESTIGATOR

CHU de Saint Etienne

Locations

CHU de Saint Etienne

Saint-Etienne, , France

Countries

France

Other Identifiers

2018-003233-14

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

18CH129

Identifier Type: -

Identifier Source: org_study_id